Patent · US Active

TLR9 targeted therapeutics

US11123435B2 · kind B2 · utility

0Cited by

103References

5Claims

0Family size

Assignees

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US
University of South Florida · US

Inventors

Alan F. List · Tampa, US
Sheng Wei · Tampa, US
Mark McLaughlin · Tampa, US

Key dates

Filing date	Aug 2, 2017
Grant date	Sep 21, 2021
Priority date	—
Expiry date	Aug 2, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.